Bettina Hamelin
Dr. Bettina Hamelin, PharmD, EMBA, is the President of Innovative Medicines Canada (IMC) and a respected life sciences leader with over 30 years of experience in academia, industry, and non-profits. She is dedicated to advancing Canada’s healthcare landscape by promoting access to innovative medicines and fostering a vibrant life sciences sector. Previously, Dr. Hamelin led Ontario Genomics and held key roles at NSERC, BioChem Pharma, and Pfizer.
Dr. Bettina Hamelin, PharmD, EMBA, is the President of Innovative Medicines Canada (IMC) and a respected life sciences leader with over 30 years of experience in academia, industry, and non-profits. She is dedicated to advancing Canada’s healthcare landscape by promoting access to innovative medicines and fostering a vibrant life sciences sector. Previously, Dr. Hamelin led Ontario Genomics and held key roles at NSERC, BioChem Pharma, and Pfizer.
Articles: Bettina Hamelin
G7 Canada: An Opportunity to Unlock the Potential of Life Sciences
Canada / Dr David Reddy, Director General, IFPMA, and Dr Bettina Hamelin, President, IMC, jointly advocate for health innovation at the 2025 G7 Summit in Kananaskis (15-17 June). They call G7 leaders to place health and life-sciences innovation at the heart of the G7 agenda, emphasizing three areas of focus where the pharmaceutical industry can drive impact:…
Latest Report
